SABR and LuPSMA for mHSPC? Let's talk LUNAR

Dr Amar Kishan (Radiation Oncologist, UCLA, USA), made lots of headlines recently when he presented data from the phase II randomised LUNAR trial of SABR +/- LuPSMA in patients with oligometastatic prostate cancer. So we were very happy when he turned up in Melbourne recently and popped into the GU Cast studio for a chat. We discuss metastasis-directed therapy and bring up our favourite Pokemet analogies, and ask should we not just be offering these patients and ADT/ARPI doublet?! Regu...